Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment

Autor(es)

Polli Silvestre, Amanda Leticia ^[1] ; Oshiro-Junior, Joao Augusto ^[2] ; Garcia, Camila ^[1] ; Turco, Bruna Ortolani ^[1] ; da Silva Leite, Joandra Maisa ^[2] ; Goulart de Lima Damasceno, Bolivar Ponciano ^[2] ; Maduro Soares, Jonas Corsino ^[1] ; Chorilli, Marlus ^[1]

Afiliação do(s) autor(es)

^[1] UNESP Sao Paulo State Univ, Sch Pharmaceut Sci, Rodovia Araraquara Jau, Km 1, BR-14800903 Araraquara, SP - Brazil

^[2] State Univ Paraiba, Grad Program Pharmaceut Sci, Joao Pessoa, Paraiba - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: Current Medicinal Chemistry; v. 28, n. 2, p. 401-418, 2021.
• Citações Web of Science: 1

Resumo

Monoclonal antibodies carried in nanosystems have been extensively studied and reported as a promising tool for the treatment of various types of cancers. Monoclonal antibodies have great advantages for the treatment of cancer because their protein structure can bind to the target tissue; however, it has some challenges such as denaturation following heat exposure and extreme values of pH, temperature and solvents, the ability to undergo hydrolysis, oxidation and deamination and the formation of non-native aggregates, which compromise drug stability to a large extent. In addition to these characteristics, they suffer rapid elimination when in the blood, which results in a short half-life and the production of neutralizing antibodies, rendering the doses ineffective. These challenges are overcome with encapsulation in nanosystems (liposomes, polymer nanoparticles, cyclodextrins, solid lipid nanoparticles, nanostructured lipid carriers, dendrimers and micelles) due to the characteristics of improving solubility, permeability, and selectivity only with tumor tissue; with that, there is a decrease in side effects beyond controlled release, which is critical to improving the therapeutic efficacy of cancer treatment. The article was divided into different types of nanosystems, with a description of their definitions and applications in various types of cancers. Therefore, this review summarizes the use of monoclonal antibodies encapsulated in nanosystems and the description of clinical studies with biosimilars. Biosimilars are defined as products that are similar to monoclonal antibodies which are produced when the patent for the monoclonal antibodies expires. (AU)

• Processo FAPESP: 18/23096-7 - Avaliação do potencial de filmes de alginato de sódio contendo curcumina encapsulada em nanopartículas de quitosana associados à terapia fotodinâmica para o tratamento de biofilmes orais
• Beneficiário: Amanda Letícia Polli Silvestre
• Modalidade de apoio: Bolsas no Brasil - Mestrado